A new study from the Institute of Environmental Medicine (IMM), published in The Lancet Regional Health - Europe, shows that ...

A new meta-analysis suggests that active exercise may slow functional decline in ALS, while noninvasive brain stimulation ...

Dazucorilant failed to slow disease progression in ALS patients in the DAZALS Phase 2 clinical trial, but may have extended ...

Researchers from the Structural Biology Brussels group at Vrije Universiteit Brussel (VUB) have uncovered a significant ...

The experimental therapy Bravyl significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of ALS.

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

Neurizon has reported positive eight-month interim data from its open-label extension study in patients with ALS (motor ...

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces ...